{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:25:47Z","timestamp":1790961947525,"version":"4.1.0"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"am","delay-in-days":341,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK103616"],"award-info":[{"award-number":["DK103616"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001824","name":"Grantov\u00e1 Agentura \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["18-03207S"],"award-info":[{"award-number":["18-03207S"]}],"id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.bcp.2021.114866","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T02:13:08Z","timestamp":1638411188000},"page":"114866","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Epoxylipids and soluble epoxide hydrolase in heart diseases"],"prefix":"10.1016","volume":"195","author":[{"given":"John D.","family":"Imig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludek","family":"Cervenka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Neckar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2021.114866_b0005","first-page":"8","article-title":"Epidemiology of cardiovascular disease in Europe","author":"Townsend","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"issue":"3","key":"10.1016\/j.bcp.2021.114866_b0010","doi-asserted-by":"crossref","first-page":"231","DOI":"10.23736\/S2724-5683.21.05538-9","article-title":"Cardiovascular disease burden: Italian and global perspectives","volume":"69","author":"Saglietto","year":"2021","journal-title":"Minerva Cardiol. Angiol."},{"issue":"3","key":"10.1016\/j.bcp.2021.114866_b0015","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2174\/1573403X14666180222102312","article-title":"Management of Measurable Variable Cardiovascular Disease' Risk Factors","volume":"14","author":"Francula-Zaninovic","year":"2018","journal-title":"Curr. Cardiol. Rev."},{"key":"10.1016\/j.bcp.2021.114866_b0020","first-page":"1","article-title":"An appeal to our government for nationwide policies in the prevention of cardiovascular disease","volume":"4","author":"van Trier","year":"2021","journal-title":"Neth. Heart J."},{"issue":"1","key":"10.1016\/j.bcp.2021.114866_b0025","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.14797\/VUWD7697","article-title":"Using Patient-Reported Outcomes to Assess Healthcare Quality: Toward Better Measurement of Patient-Centered Care in Cardiovascular Disease","volume":"17","author":"Garcia","year":"2021","journal-title":"Methodist Debakey Cardiovasc. J."},{"issue":"2","key":"10.1016\/j.bcp.2021.114866_b0030","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1161\/CIR.0000000000000981","article-title":"A Call to Action for New Global Approaches to Cardiovascular Disease Drug Solutions","volume":"144","author":"Figtree","year":"2021","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.bcp.2021.114866_b0035","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2147\/IBPC.S324151","article-title":"Predictive Factors for Target Organ Injuries in Hypertensive Individuals","volume":"14","author":"Paz Landim","year":"2021","journal-title":"Integr. Blood Press Control."},{"issue":"1 Suppl","key":"10.1016\/j.bcp.2021.114866_b0040","doi-asserted-by":"crossref","first-page":"3A","DOI":"10.1016\/j.amjcard.2009.10.007","article-title":"Cardiovascular disease risk factors: epidemiology and risk assessment","volume":"105","author":"Dahl\u00f6f","year":"2010","journal-title":"Am. J. Cardiol."},{"issue":"Suppl 2","key":"10.1016\/j.bcp.2021.114866_b0045","doi-asserted-by":"crossref","first-page":"S314","DOI":"10.2337\/dc09-S330","article-title":"Endothelial dysfunction as a target for prevention of cardiovascular disease","volume":"32","author":"Versari","year":"2009","journal-title":"Diabetes Care."},{"issue":"22","key":"10.1016\/j.bcp.2021.114866_b0050","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1161\/hc4601.099485","article-title":"Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease","volume":"104","author":"Heitzer","year":"2001","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.bcp.2021.114866_b0055","doi-asserted-by":"crossref","first-page":"H2181","DOI":"10.1152\/ajpheart.00554.2011","article-title":"Oxidative stress and heart failure","volume":"301","author":"Tsutsui","year":"2011","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"2","key":"10.1016\/j.bcp.2021.114866_b0060","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.bbadis.2014.05.005","article-title":"Autophagy and oxidative stress in cardiovascular diseases","volume":"1852","author":"Mei","year":"2015","journal-title":"Biochim Biophys. Acta"},{"issue":"1","key":"10.1016\/j.bcp.2021.114866_b0065","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1161\/HYPERTENSIONAHA.120.13898","article-title":"Epoxy Fatty Acids: From Salt Regulation to Kidney and Cardiovascular Therapeutics: 2019 Lewis K Dahl Memorial Lecture","volume":"76","author":"Imig","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2021.114866_b0070","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.pharmthera.2017.05.005","article-title":"Cytochrome P450-derived eicosanoids and heart function","volume":"179","author":"Jamieson","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2021.114866_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2018.06.015","article-title":"Prospective for cytochrome P450 epoxygenase cardiovascular and renal therapeutics","volume":"192","author":"Imig","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2021.114866_b0080","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pharmthera.2017.10.016","article-title":"Therapeutic potential of omega-3 fatty acid-derived epoxyeicosanoids in cardiovascular and inflammatory diseases","volume":"183","author":"Schunck","year":"2018","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2021.114866_b0085","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1152\/physrev.00021.2011","article-title":"Epoxides and soluble epoxide hydrolase in cardiovascular physiology","volume":"92","author":"Imig","year":"2012","journal-title":"Physiol. Rev."},{"issue":"10","key":"10.1016\/j.bcp.2021.114866_b0090","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/nrd2875","article-title":"Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases","volume":"8","author":"Imig","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.bcp.2021.114866_b0095","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/FJC.0b013e318273b007","article-title":"Epoxyeicosatrienoic acid pathway in human health and diseases","volume":"61","author":"Bellien","year":"2013","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"10","key":"10.1016\/j.bcp.2021.114866_b0100","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1161\/CIRCULATIONAHA.111.070680","article-title":"Epoxyeicosatrienoic acids contribute with altered nitric oxide and endothelin-1 pathways to conduit artery endothelial dysfunction in essential hypertension","volume":"125","author":"Bellien","year":"2012","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.bcp.2021.114866_b0105","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.3390\/ijms19071916","article-title":"Regulation of CYP2J2 and EET Levels in Cardiac Disease and Diabetes","volume":"19","author":"Aliwarga","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"15","key":"10.1016\/j.bcp.2021.114866_b0110","first-page":"15","article-title":"CYP2C19 variants and epoxyeicosatrienoic acids in patients with microvascular angina","volume":"12","author":"Akasaka","year":"2017","journal-title":"Int J Cardiol. Heart Vasc."},{"issue":"2","key":"10.1016\/j.bcp.2021.114866_b0115","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.atherosclerosis.2012.03.022","article-title":"Evaluation of cytochrome P450-derived eicosanoids in humans with stable atherosclerotic cardiovascular disease","volume":"222","author":"Theken","year":"2012","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1016\/j.bcp.2021.114866_b0120","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/FPC.0b013e3283485eb2","article-title":"Association between polymorphisms of CYP2J2 and EPHX2 genes and risk of coronary artery disease","volume":"21","author":"Xu","year":"2011","journal-title":"Pharmacogenet. Genomics"},{"issue":"4","key":"10.1016\/j.bcp.2021.114866_b0125","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1080\/10641963.2016.1246562","article-title":"The contribution of CYP2C gene subfamily involved in epoxygenase pathway of arachidonic acids metabolism to hypertension susceptibility in Russian population","volume":"39","author":"Polonikov","year":"2017","journal-title":"Clin. Exp. Hypertens."},{"issue":"Pt 4","key":"10.1016\/j.bcp.2021.114866_b0130","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1469-1809.2007.00346.x","article-title":"Evidence for association of polymorphisms in CYP2J2 and susceptibility to essential hypertension","volume":"71","author":"Wu","year":"2007","journal-title":"Ann. Hum. Genet."},{"issue":"11","key":"10.1016\/j.bcp.2021.114866_b0135","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1042\/CS20110215","article-title":"Cytochrome P450 metabolites of arachidonic acid are elevated in stroke patients compared with healthy controls","volume":"121","author":"Ward","year":"2011","journal-title":"Clin. Sci. (Lond)."},{"issue":"5","key":"10.1016\/j.bcp.2021.114866_b0140","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/ng.129","article-title":"Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease","volume":"40","author":"Monti","year":"2008","journal-title":"Nat. Genet."},{"issue":"3 Pt 2","key":"10.1016\/j.bcp.2021.114866_b0145","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1161\/01.HYP.0000047877.36743.FA","article-title":"Decreased renal cytochrome P450 2C enzymes and impaired vasodilation are associated with angiotensin salt-sensitive hypertension","volume":"41","author":"Zhao","year":"2003","journal-title":"Hypertension"},{"issue":"2 Pt 2","key":"10.1016\/j.bcp.2021.114866_b0150","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1161\/hy0202.103788","article-title":"Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension","volume":"39","author":"Imig","year":"2002","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.bcp.2021.114866_b0155","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1161\/01.HYP.0000153792.29478.1d","article-title":"Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension","volume":"45","author":"Jung","year":"2005","journal-title":"Hypertension"},{"issue":"10","key":"10.1016\/j.bcp.2021.114866_b0160","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1096\/fj.10-160119","article-title":"Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice","volume":"24","author":"Lee","year":"2010","journal-title":"FASEB J."},{"issue":"4","key":"10.1016\/j.bcp.2021.114866_b0165","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1161\/01.RES.0000237390.92932.37","article-title":"Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function","volume":"99","author":"Seubert","year":"2006","journal-title":"Circ. Res."},{"key":"10.1016\/j.bcp.2021.114866_b0170","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.freeradbiomed.2018.02.009","article-title":"CYP2J2-derived EETs attenuated ethanol-induced myocardial dysfunction through inducing autophagy and reducing apoptosis","volume":"117","author":"Zhou","year":"2018","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.bcp.2021.114866_b0175","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.prostaglandins.2015.01.004","article-title":"CYP epoxygenase 2J2 prevents cardiac fibrosis by suppression of transmission of pro-inflammation from cardiomyocytes to macrophages","volume":"116\u2013117","author":"Yang","year":"2015","journal-title":"Prostaglandins Other Lipid Mediat."},{"issue":"3","key":"10.1016\/j.bcp.2021.114866_b0180","doi-asserted-by":"crossref","first-page":"F740","DOI":"10.1152\/ajprenal.00098.2009","article-title":"Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension","volume":"297","author":"Manhiani","year":"2009","journal-title":"Am. J. Physiol. Renal. Physiol."},{"issue":"4","key":"10.1016\/j.bcp.2021.114866_b0185","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/FJC.0000000000000523","article-title":"Orally Active Epoxyeicosatrienoic Acid Analogs","volume":"70","author":"Campbell","year":"2017","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"1\u20134","key":"10.1016\/j.bcp.2021.114866_b0190","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.prostaglandins.2006.05.017","article-title":"Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia\/reperfusion injury","volume":"82","author":"Seubert","year":"2007","journal-title":"Prostaglandins Other Lipid Mediat."},{"issue":"8","key":"10.1016\/j.bcp.2021.114866_b0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160380","article-title":"Novel Roles of Epoxyeicosanoids in Regulating Cardiac Mitochondria","volume":"11","author":"El-Sikhry","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2021.114866_b0200","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.yjmcc.2013.02.003","article-title":"Roles of endothelial nitric oxide synthase (eNOS) and mitochondrial permeability transition pore (MPTP) in epoxyeicosatrienoic acid (EET)-induced cardioprotection against infarction in intact rat hearts","volume":"59","author":"Gross","year":"2013","journal-title":"J. Mol. Cell Cardiol."},{"issue":"3","key":"10.1016\/j.bcp.2021.114866_b0205","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/FJC.0b013e31827afcee","article-title":"Effect of ischemia reperfusion injury and epoxyeicosatrienoic acids on caveolin expression in mouse myocardium","volume":"61","author":"Chaudhary","year":"2013","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2021.114866_b0210","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.yjmcc.2009.02.028","article-title":"Epoxyeicosatrienoic acids limit damage to mitochondrial function following stress in cardiac cells","volume":"46","author":"Katragadda","year":"2009","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"1","key":"10.1016\/j.bcp.2021.114866_b0215","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.yjmcc.2012.04.008","article-title":"Role of PI3K\u03b1 and sarcolemmal ATP-sensitive potassium channels in epoxyeicosatrienoic acid mediated cardioprotection","volume":"53","author":"Batchu","year":"2012","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"2","key":"10.1016\/j.bcp.2021.114866_b0220","doi-asserted-by":"crossref","first-page":"H724","DOI":"10.1152\/ajpheart.00979.2007","article-title":"Multiple antiapoptotic targets of the PI3K\/Akt survival pathway are activated by epoxyeicosatrienoic acids to protect cardiomyocytes from hypoxia\/anoxia","volume":"294","author":"Dhanasekaran","year":"2008","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"9","key":"10.1016\/j.bcp.2021.114866_b0225","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1002\/jcp.24939","article-title":"Epoxyeicosatrienoic acids regulate macrophage polarization and prevent LPS-induced cardiac dysfunction","volume":"230","author":"Dai","year":"2015","journal-title":"J. Cell. Physiol."},{"issue":"9","key":"10.1016\/j.bcp.2021.114866_b0230","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3390\/biomedicines8090306","article-title":"The Anti-Inflammatory and Antioxidant Properties of n-3 PUFAs: Their Role in Cardiovascular Protection","volume":"8","author":"Oppedisano","year":"2020","journal-title":"Biomedicines"},{"issue":"6 Suppl","key":"10.1016\/j.bcp.2021.114866_b0235","doi-asserted-by":"crossref","first-page":"1477S","DOI":"10.1093\/ajcn\/83.6.1477S","article-title":"n-3 fatty acids and cardiovascular disease","volume":"83","author":"Breslow","year":"2006","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.bcp.2021.114866_b0240","doi-asserted-by":"crossref","DOI":"10.1007\/s00394-021-02608-x","article-title":"Cardiac contractile dysfunction, during and following ischaemia, is attenuated by low-dose dietary fish oil in rats","author":"Macartney","year":"2021","journal-title":"Eur J Nutr."},{"issue":"1","key":"10.1016\/j.bcp.2021.114866_b0245","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12929-014-0101-3","article-title":"N-3 polyunsaturated fatty acids decrease levels of doxorubicin-induced reactive oxygen species in cardiomyocytes \u2013 involvement of uncoupling protein UCP2","volume":"21","author":"Hsu","year":"2014","journal-title":"J. Biomed. Sci."},{"issue":"6","key":"10.1016\/j.bcp.2021.114866_b0250","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.yjmcc.2005.08.004","article-title":"Long-chain polyunsaturated fatty acids protect the heart against ischemia\/reperfusion-induced injury via a MAPK dependent pathway","volume":"39","author":"Engelbrecht","year":"2005","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.bcp.2021.114866_b0255","doi-asserted-by":"crossref","first-page":"15054","DOI":"10.1038\/cddiscovery.2015.54","article-title":"CYP-epoxygenase metabolites of docosahexaenoic acid protect HL-1 cardiac cells against LPS-induced cytotoxicity Through SIRT1","volume":"1","author":"Samokhvalov","year":"2015","journal-title":"Cell Death Discov."},{"issue":"7-8","key":"10.1016\/j.bcp.2021.114866_b0260","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1139\/y98-079","article-title":"Individual effects of dietary EPA and DHA on the functioning of the isolated working rat heart","volume":"76","author":"Sergiel","year":"1998","journal-title":"Can. J. Physiol. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2021.114866_b0265","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1139\/cjpp-2018-0480","article-title":"Cardioprotective effects of CYP-derived epoxy metabolites of docosahexaenoic acid involve limiting NLRP3 inflammasome activation 1","volume":"97","author":"Darwesh","year":"2019","journal-title":"Can. J. Physiol. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2021.114866_b0270","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1161\/CIRCULATIONAHA.110.971853","article-title":"Omega-3 fatty acids prevent pressure overload-induced cardiac fibrosis through activation of cyclic GMP\/protein kinase G signaling in cardiac fibroblasts","volume":"123","author":"Chen","year":"2011","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.bcp.2021.114866_b0275","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1194\/jlr.M062034","article-title":"EPA, not DHA, prevents fibrosis in pressure overload-induced heart failure: potential role of free fatty acid receptor 4","volume":"56","author":"Eclov","year":"2015","journal-title":"J. Lipid Res."},{"issue":"2","key":"10.1016\/j.bcp.2021.114866_b0280","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004560","article-title":"Long-Term Administration of Eicosapentaenoic Acid Improves Post-Myocardial Infarction Cardiac Remodeling in Mice by Regulating Macrophage Polarization","volume":"6","author":"Takamura","year":"2017","journal-title":"J Am Heart Assoc."},{"issue":"20","key":"10.1016\/j.bcp.2021.114866_b0285","doi-asserted-by":"crossref","first-page":"7628","DOI":"10.3390\/ijms21207628","article-title":"The Role of Resolvins: EPA and DHA Derivatives Can Be Useful in the Prevention and Treatment of Ischemic Stroke","volume":"21","author":"Tu\u0142owiecka","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.bcp.2021.114866_b0290","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1080\/00325481.2019.1607414","article-title":"The eicosapentaenoic acid:arachidonic acid ratio and its clinical utility in cardiovascular disease","volume":"131","author":"Nelson","year":"2019","journal-title":"Postgrad. Med."},{"issue":"1","key":"10.1016\/j.bcp.2021.114866_b0295","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12872-017-0479-4","article-title":"The ratio of serum n-3 to n-6 polyunsaturated fatty acids is associated with diabetes mellitus in patients with prior myocardial infarction: a multicenter cross-sectional study","volume":"17","author":"Takahashi","year":"2017","journal-title":"BMC Cardiovasc. Disord."},{"issue":"49","key":"10.1016\/j.bcp.2021.114866_b0300","doi-asserted-by":"crossref","first-page":"18733","DOI":"10.1073\/pnas.0609158103","article-title":"Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors","volume":"103","author":"Xu","year":"2006","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"9","key":"10.1016\/j.bcp.2021.114866_b0305","doi-asserted-by":"crossref","first-page":"H1020","DOI":"10.1152\/ajpheart.00465.2014","article-title":"Soluble epoxide hydrolase inhibition improves coronary endothelial function and prevents the development of cardiac alterations in obese insulin-resistant mice","volume":"308","author":"Roche","year":"2015","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"14","key":"10.1016\/j.bcp.2021.114866_b0310","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.3390\/ijms20143502","article-title":"Genetic Deletion or Pharmacological Inhibition of Soluble Epoxide Hydrolase Ameliorates Cardiac Ischemia\/Reperfusion Injury by Attenuating NLRP3 Inflammasome Activation","volume":"20","author":"Darwesh","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.bcp.2021.114866_b0315","doi-asserted-by":"crossref","DOI":"10.1111\/1755-5922.12259","article-title":"Inhibitors of soluble epoxide hydrolase minimize ischemia-reperfusion-induced cardiac damage in normal, hypertensive, and diabetic rats","volume":"35","author":"Islam","year":"2017","journal-title":"Cardiovasc. Ther."},{"issue":"6","key":"10.1016\/j.bcp.2021.114866_b0320","doi-asserted-by":"crossref","first-page":"H2838","DOI":"10.1152\/ajpheart.00186.2008","article-title":"Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart","volume":"294","author":"Gross","year":"2008","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"7","key":"10.1016\/j.bcp.2021.114866_b0325","first-page":"133","article-title":"Inhibition of Soluble Epoxide Hydrolase Limits Mitochondrial Damage and Preserves Function Following Ischemic Injury","volume":"7","author":"Akhnokh","year":"2016","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2021.114866_b0330","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/FJC.0b013e3181c37d69","article-title":"Inhibition of soluble epoxide hydrolase by trans-4- [4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid is protective against ischemia-reperfusion injury","volume":"55","author":"Chaudhary","year":"2010","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2021.114866_b0335","doi-asserted-by":"crossref","first-page":"H679","DOI":"10.1152\/ajpheart.00533.2009","article-title":"Inhibition of soluble epoxide hydrolase preserves cardiomyocytes: role of STAT3 signaling","volume":"298","author":"Merkel","year":"2010","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"2","key":"10.1016\/j.bcp.2021.114866_b0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2020.112360","article-title":"Soluble epoxide hydrolase inhibitors improve angiogenic function of endothelial progenitor cells via ERK\/p38-mediated miR-126 upregulation in myocardial infarction mice after exercise","volume":"397","author":"Gui","year":"2020","journal-title":"Exp. Cell Res."},{"issue":"6","key":"10.1016\/j.bcp.2021.114866_b0345","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1139\/y2012-082","article-title":"Novel soluble epoxide hydrolase inhibitor protects mitochondrial function following stress","volume":"90","author":"Batchu","year":"2012","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.bcp.2021.114866_b0350","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.yjmcc.2014.05.016","article-title":"Epoxyeicosatrienoic acids and cardioprotection: the road to translation","volume":"74","author":"Oni-Orisan","year":"2014","journal-title":"J. Mol. Cell Cardiol."},{"issue":"6","key":"10.1016\/j.bcp.2021.114866_b0355","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.yjmcc.2009.08.017","article-title":"Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: Insight gained using metabolomic approaches","volume":"47","author":"Li","year":"2009","journal-title":"J. Mol. Cell Cardiol."},{"issue":"1","key":"10.1016\/j.bcp.2021.114866_b0360","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ijcard.2011.12.062","article-title":"Soluble epoxide hydrolase inhibition exerts beneficial anti-remodeling actions post-myocardial infarction","volume":"167","author":"Kompa","year":"2013","journal-title":"Int. J. Cardiol."},{"issue":"14","key":"10.1016\/j.bcp.2021.114866_b0365","doi-asserted-by":"crossref","first-page":"5618","DOI":"10.1073\/pnas.1221972110","article-title":"Unique mechanistic insights into the beneficial effects of soluble epoxide hydrolase inhibitors in the prevention of cardiac fibrosis","volume":"110","author":"Sirish","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"issue":"5","key":"10.1016\/j.bcp.2021.114866_b0370","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.115.003721","article-title":"Molecular Mechanisms and New Treatment Paradigm for Atrial Fibrillation","volume":"9","author":"Sirish","year":"2016","journal-title":"Circ. Arrhythm. Electrophysiol."},{"issue":"11","key":"10.1016\/j.bcp.2021.114866_b0375","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1042\/CS20110622","article-title":"Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension","volume":"122","author":"Neck\u00e1\u0159","year":"2012","journal-title":"Clin. Sci. (Lond)."},{"issue":"10","key":"10.1016\/j.bcp.2021.114866_b0380","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fphar.2019.00018","article-title":"Pharmacological Blockade of Soluble Epoxide Hydrolase Attenuates the Progression of Congestive Heart Failure Combined With Chronic Kidney Disease: Insights From Studies With Fawn-Hooded Hypertensive Rats","volume":"23","author":"Vackov\u00e1","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.bcp.2021.114866_b0385","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/jphp.13113","article-title":"Soluble epoxide hydrolase inhibitor, TUPS, attenuates isoproterenol\/angiotensin II-induced cardiac hypertrophy through mammalian target of rapamycin-mediated autophagy inhibition","volume":"71","author":"Zhang","year":"2019","journal-title":"J. Pharm. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2021.114866_b0390","doi-asserted-by":"crossref","first-page":"857","DOI":"10.33549\/physiolres.932977","article-title":"Inhibition of soluble epoxide hydrolase does not improve the course of congestive heart failure and the development of renal dysfunction in rats with volume overload induced by aorto-caval fistula","volume":"64","author":"\u010cervenka","year":"2015","journal-title":"Physiol. Res."},{"key":"10.1016\/j.bcp.2021.114866_b0395","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.prostaglandins.2015.01.002","article-title":"Agonists of epoxyeicosatrienoic acids reduce infarct size and ameliorate cardiac dysfunction via activation of HO-1 and Wnt1 canonical pathway","volume":"116\u2013117","author":"Cao","year":"2015","journal-title":"Prostaglandins Other Lipid Mediat."},{"issue":"4","key":"10.1016\/j.bcp.2021.114866_b0400","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/j.1476-5381.2010.01093.x","article-title":"Cardioprotective effect of a dual acting epoxyeicosatrienoic acid analogue towards ischaemia reperfusion injury","volume":"162","author":"Batchu","year":"2011","journal-title":"Br. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2021.114866_b0405","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1097\/HJH.0000000000001708","article-title":"Two pharmacological epoxyeicosatrienoic acid-enhancing therapies are effectively antihypertensive and reduce the severity of ischemic arrhythmias in rats with angiotensin II-dependent hypertension","volume":"36","author":"\u010cervenka","year":"2018","journal-title":"J. Hypertens"},{"issue":"8","key":"10.1016\/j.bcp.2021.114866_b0410","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.3390\/biomedicines9081053","article-title":"Effects of Epoxyeicosatrienoic Acid-Enhancing Therapy on the Course of Congestive Heart Failure in Angiotensin II-Dependent Rat Hypertension: From mRNA Analysis towards Functional In Vivo Evaluation","volume":"9","author":"Kala","year":"2021","journal-title":"Biomedicines"},{"issue":"5","key":"10.1016\/j.bcp.2021.114866_b0415","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1161\/HYPERTENSIONAHA.113.01949","article-title":"Orally active epoxyeicosatrienoic acid analog attenuates kidney injury in hypertensive Dahl salt-sensitive rat","volume":"62","author":"Hye Khan","year":"2013","journal-title":"Hypertension"},{"issue":"8","key":"10.1016\/j.bcp.2021.114866_b0420","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1042\/CS20180728","article-title":"Epoxyeicosatrienoic acid analog EET-B attenuates post-myocardial infarction remodeling in spontaneously hypertensive rats","volume":"133","author":"Neck\u00e1\u0159","year":"2019","journal-title":"Clin Sci (Lond)."},{"issue":"5","key":"10.1016\/j.bcp.2021.114866_b0425","doi-asserted-by":"crossref","first-page":"H1148","DOI":"10.1152\/ajpheart.00726.2017","article-title":"Infarct size-limiting effect of epoxyeicosatrienoic acid analog EET-B is mediated by hypoxia-inducible factor-1\u03b1 via downregulation of prolyl hydroxylase 3","volume":"315","author":"Neck\u00e1\u0159","year":"2018","journal-title":"Am J Physiol Heart Circ Physiol."},{"issue":"10","key":"10.1016\/j.bcp.2021.114866_b0430","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3389\/fphar.2019.00159","article-title":"Epoxyeicosatrienoic Acid-Based Therapy Attenuates the Progression of Postischemic Heart Failure in Normotensive Sprague-Dawley but Not in Hypertensive Ren-2 Transgenic Rats","volume":"1","author":"Hrdli\u010dka","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2021.114866_b0435","first-page":"401","article-title":"Effect of angiotensin-converting enzyme blockade, alone or combined with blockade of soluble epoxide hydrolase, on the course of congestive heart failure and occurrence of renal dysfunction in Ren-2 transgenic hypertensive rats with aorto-caval fistula","volume":"67","author":"Kala","year":"2018","journal-title":"Physiol. Res."},{"issue":"22","key":"10.1016\/j.bcp.2021.114866_b0440","first-page":"10124","article-title":"Development of Robust 17(R),18(S)-Epoxyeicosatetraenoic Acid (17,18-EEQ) Analogues as Potential Clinical Antiarrhythmic Agents","volume":"62","author":"Adebesin","year":"2019","journal-title":"J. Med. Chem."},{"issue":"15","key":"10.1016\/j.bcp.2021.114866_b0445","doi-asserted-by":"crossref","first-page":"5261","DOI":"10.3390\/ijms21155261","article-title":"A Synthetic Epoxydocosapentaenoic Acid Analogue Ameliorates Cardiac Ischemia\/Reperfusion Injury: The Involvement of the Sirtuin 3-NLRP3 Pathway","volume":"21","author":"Darwesh","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2021.114866_b0450","unstructured":"W.H. Schunck, G. Wallukat, R. Fischer, C. Schmidt, D.N. M\u00fcller, N. Puli, J.R. Falck, Novel eicosanoid derivatives. 2010 (WO 2010\/081683)."},{"key":"10.1016\/j.bcp.2021.114866_b0455","unstructured":"R. Fischer, A. Konkel, T. Wesser, P. Westphal, W.H. Schunck, C. Westphal, J.R. Falck, Metabolically robust analogs of Cyp-eicosanoids for the treatment of cardiac disease. 2017 (WO 2017\/013265)."},{"issue":"12","key":"10.1016\/j.bcp.2021.114866_b0460","article-title":"Sacubitril\/Valsartan as a Therapeutic Tool Across the Range of Heart Failure Phenotypes and Ejection Fraction Spectrum","volume":"23","author":"Gallo","year":"2021","journal-title":"Front. Physiol."},{"key":"10.1016\/j.bcp.2021.114866_b0465","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.554961","article-title":"Multi-Target Approaches in Metabolic Syndrome","volume":"11","author":"Lillich","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2021.114866_b0470","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.prostaglandins.2016.07.003","article-title":"A dual COX-2\/sEH inhibitor improves the metabolic profile and reduces kidney injury in Zucker diabetic fatty rat","volume":"125","author":"Hye Khan","year":"2016","journal-title":"Prostaglandins Other Lipid Mediat."},{"issue":"10","key":"10.1016\/j.bcp.2021.114866_b0475","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1007\/s00125-018-4685-0","article-title":"A novel dual PPAR-\u03b3 agonist\/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes","volume":"61","author":"Hye Khan","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.bcp.2021.114866_b0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.prostaglandins.2020.106472","article-title":"Dual soluble epoxide hydrolase inhibitor\/PPAR-\u03b3 agonist attenuates renal fibrosis","volume":"150","author":"Stavniichuk","year":"2020","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"10.1016\/j.bcp.2021.114866_b0485","doi-asserted-by":"crossref","unstructured":"J.R. Falck, S.R. Koduru, S. Mohapatra, R. Manne, K.R. Atcha, R. Atcha, V.L. Manthati, J.H. Capdevila, S. Christian, J.D. Imig, W.B. Campbell, 14,15-Epoxyeicosa-5,8,11-trienoic Acid (14,15-EET) surrogates: carboxylate modifications. J. Med. Chem. 57(16) (2014) 6965-6972. doi: 10.1021\/jm500262m. Epub 2014 Aug 19. Erratum in: J Med Chem. 2014 Nov 13;57(21):9218. Atcha, Krishnam Raju [added]. PMID: 25119815; PMCID: PMC4148164.","DOI":"10.1021\/jm500262m"},{"issue":"11","key":"10.1016\/j.bcp.2021.114866_b0490","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1161\/CIRCRESAHA.116.310525","article-title":"20-HETE Signals Through G-Protein-Coupled Receptor GPR75 (Gq) to Affect Vascular Function and Trigger Hypertension","volume":"120","author":"Garcia","year":"2017","journal-title":"Circ. Res."},{"issue":"18","key":"10.1016\/j.bcp.2021.114866_b0495","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1111\/bph.15525","article-title":"Uncovering the signalling, structure and function of the 20-HETE-GPR75 pairing: Identifying the chemokine CCL5 as a negative regulator of GPR75","volume":"178","author":"Pascale","year":"2021","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2021.114866_b0500","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0090-6980(00)00079-4","article-title":"Mechanism and signal transduction of 14 (R), 15 (S)-epoxyeicosatrienoic acid (14,15-EET) binding in guinea pig monocytes","volume":"62","author":"Wong","year":"2000","journal-title":"Prostaglandins Other Lipid Mediat."},{"issue":"3","key":"10.1016\/j.bcp.2021.114866_b0505","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1124\/jpet.107.119651","article-title":"Characterization of 14,15-epoxyeicosatrienoyl-sulfonamides as 14,15-epoxyeicosatrienoic acid agonists: use for studies of metabolism and ligand binding","volume":"321","author":"Yang","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.bcp.2021.114866_b0510","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1124\/jpet.107.129577","article-title":"Characterization of epoxyeicosatrienoic acid binding site in U937 membranes using a novel radiolabeled agonist, 20\u2013125i-14,15-epoxyeicosa-8(Z)-enoic acid","volume":"324","author":"Yang","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295221004925?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295221004925?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:25:16Z","timestamp":1757769916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295221004925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":102,"alternative-id":["S0006295221004925"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2021.114866","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epoxylipids and soluble epoxide hydrolase in heart diseases","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2021.114866","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114866"}}